Skip to Content
Find More Like This
Return to Search

Predictive and therapeutic markers in ovarian cancer

United States Patent

March 26, 2013
View the Complete Patent at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.
Gray; Joe W. (San Francisco, CA), Guan; Yinghui (South San Francisco, CA), Kuo; Wen-Lin (San Ramon, CA), Fridlyand; Jane (San Francisco, CA), Mills; Gordon B. (Houston, TX)
The Regents of the University of California (Oakland, CA), The Board of Regents, University of Texas System (Austin, TX)
11/ 814,798
January 19, 2006
STATEMENT OF GOVERNMENTAL SUPPORT This invention was made during work supported by the National Cancer Institute, through Grants CA 58207 and CA 64602 and during work supported by the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. The government has certain rights in this invention.